


**Amendments to the Claims**

Please amend the claims as follows:

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Previously presented) A compound of the formula:



Formula III

wherein


R<sup>1</sup> is hydrogen or methyl;

R<sup>a</sup> is hydrogen; hydroxy; (C1-C4)alkoxy; or -O(CH<sub>2</sub>)<sub>2</sub>N-morpholino;

and the pharmaceutically acceptable salts thereof.

5. (Currently amended) A compound according to claim 4 selected from the group consisting of:
  - a. 3-quinolin-4-yl-2-pyridin-2-yl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepine;
  - b. (7-Methoxy-quinolin-4-yl)-2-pyridin-2-yl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5a]azepine;
  - c. 4-(2-Pyridin-2-yl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-quinolin-7-ol; and
  - d. 3-[7-(2-Morpholin-4-yl-ethoxy)-quinolin-4-yl]-2-pyridin-2-yl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepine.

6. (Previously presented) A method of treating breast cancer comprising administering to a patient in need thereof a compound of the formula:



Formula III


wherein

R<sup>1</sup> is hydrogen or methyl;

R<sup>a</sup> is hydrogen; hydroxy; (C1-C4)alkoxy; or -O(CH<sub>2</sub>)<sub>2</sub>N-morpholino;

and the pharmaceutically acceptable salts thereof.

7. (Previously presented) A pharmaceutical formulation comprising a compound of the formula:



Formula III

wherein

R<sup>1</sup> is hydrogen or methyl;

R<sup>a</sup> is hydrogen; hydroxy; (C1-C4)alkoxy; or -O(CH<sub>2</sub>)<sub>2</sub>N-morpholino;

and the pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable diluent, carrier, or excipient.